We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$10.2B
1-Year Est. Return
149.19%
This Fund
S&P 500
This Quarter
Est. Return
+52.07%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.73B
AUM Growth
+$2.02B
(+35%)
Cap. Flow
-$92.9M
Cap. Flow
% of AUM
-1.2%
Top 10 Holdings %
Top 10 Hldgs %
72.49%
Holding
33
New
3
Increased
11
Reduced
11
Closed
3
Top Buys
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$103M |
| 2 |
Structure Therapeutics
GPCR
|
+$103M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$39.1M |
| 4 |
Ocular Therapeutix
OCUL
|
+$34.1M |
| 5 |
MRUS
Merus
MRUS
|
+$25.2M |
Top Sells
| 1 |
argenx
ARGX
|
+$122M |
| 2 |
United Therapeutics
UTHR
|
+$117M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
+$112M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$48.1M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$27.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$17.4B
| $1.02B | 13.14% |
5,110,000
+130,000
| +3% | +$24.2M |
|
|
2
United Therapeutics
UTHR
$22.7B
| $848M | 10.97% |
2,022,222
-347,778
| -15% | -$117M |
|
3
Madrigal Pharmaceuticals
MDGL
$12.2B
| $841M | 10.88% |
1,833,000
-42,000
| -2% | -$15.7M |
|
|
4
argenx
ARGX
$54.5B
| $730M | 9.45% |
990,000
-185,000
| -16% | -$122M |
|
5
Krystal Biotech
KRYS
$10.7B
| $490M | 6.34% |
2,777,777
+117,777
| +4% | +$17.6M |
|
6
Arrowhead Research
ARWR
$10.4B
| $376M | 4.86% |
10,900,000
+300,000
| +3% | +$6.6M |
|
7
Kymera Therapeutics
KYMR
$9.08B
| $359M | 4.65% |
6,350,000
-205,555
| -3% | -$9.27M |
|
|
MRUS
8
DELISTED
Merus
MRUS
| $334M | 4.31% |
3,542,500
+386,945
| +12% | +$25.2M |
|
|
RNAM
9
DELISTED
Avidity Biosciences
RNAM
| $333M | 4.31% |
7,645,000
+595,000
| +8% | +$24.1M |
|
|
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
| $277M | 3.58% |
12,222,222
| – | – |
|
|
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
| $262M | 3.39% |
10,808,080
+5,808,080
| +116% | +$103M |
|
12
uniQure
QURE
$2.83B
| $259M | 3.36% |
4,444,444
+819,444
| +23% | +$14.9M |
|
13
Xenon Pharmaceuticals
XENE
$6.55B
| $217M | 2.8% |
5,400,000
| – | – |
|
|
AKRO
14
DELISTED
Akero Therapeutics
AKRO
| $188M | 2.43% |
3,955,555
+455,555
| +13% | +$22.1M |
|
15
Vera Therapeutics
VERA
$2.98B
| $180M | 2.33% |
6,210,000
-90,000
| -1% | -$2.08M |
|
|
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
| $174M | 2.25% |
2,577,777
+527,777
| +26% | +$39.1M |
|
|
17
Structure Therapeutics
GPCR
$3.67B
| $144M | 1.87% |
+5,155,555
| New | +$103M |
|
|
TRML
18
DELISTED
Tourmaline Bio
TRML
| $122M | 1.58% |
2,555,555
| – | – |
|
|
19
Ocular Therapeutix
OCUL
$2.16B
| $120M | 1.55% |
10,250,000
+2,850,000
| +39% | +$34.1M |
|
|
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
| $118M | 1.53% |
15,025,000
-2,975,000
| -17% | -$21.2M |
|
|
ETNB
21
DELISTED
89bio
ETNB
| $93.9M | 1.21% |
6,387,790
-362,210
| -5% | -$3.69M |
|
22
Taysha Gene Therapies
TSHA
$1.55B
| $71M | 0.92% |
21,700,000
| – | – |
|
23
Alkermes
ALKS
$8.65B
| $67.2M | 0.87% |
2,240,000
-660,000
| -23% | -$18.6M |
|
|
ORKA
24
Oruka Therapeutics
ORKA
$5.1B
| $25.6M | 0.33% |
+1,333,340
| New | +$19.8M |
|
|
SEPN
25
Septerna Inc
SEPN
$1.55B
| $25.2M | 0.33% |
1,337,500
+100,000
| +8% | +$1.31M |
|
Similar funds
GI
IIM
RA
GT
VPIM
OIA
ECM
BEI